COVID-19 investigational treatments in use among hospitalized patients identified through the U.S. Coronavirus Disease 2019 -Associated Hospitalization Surveillance Network, March 1–June 30, 2020
2020
Using a coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network, we found that 42.5% of hospitalized COVID-19 cases with available data from March 1-June 30, 2020, received ≥1 COVID-19 investigational treatment. Hydroxychloroquine, azithromycin, and remdesivir were used frequently; however, hydroxychloroquine and azithromycin use declined over time, while use of remdesivir increased.
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
9
References
3
Citations
NaN
KQI